ArticlePLoS neglected tropical diseases2022
The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020.
Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Prevalence of African animal trypanosomiasis among livestock and domestic animals in Uganda: a systematic review and meta-regression analysis from 1980 to 2022.Scientific reports · 2023Pooled it
- African animal trypanocide resistance: A systematic review and meta-analysis.Frontiers in veterinary science · 2022Pooled it
- Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study.The Lancet. Global health · 2025Trial
- Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.The Lancet. Infectious diseases · 2023Trial
- Performance of clinical signs and symptoms, rapid and reference laboratory diagnostic tests for diagnosis of human African trypanosomiasis by passive screening in Guinea: a prospective diagnostic accuracy study.Infectious diseases of poverty · 2023Trial
- Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study.Clinical pharmacokinetics · 2023Trial
- Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study.EBioMedicine · 2022Trial
- Comparative evaluation of the attractiveness of new polyethylene screens versus West African tiny target for the control of tsetse flies.Medical and veterinary entomology · 2026Article
- Acoziborole: First Approval.Drugs · 2026Review
- Modeling framework to demonstrate elimination of a vector population: Tsetse elimination in Chad.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Xeno-monitoring the impact of Vector Control on trypanosome transmission in the Forecariah sleeping sickness focus (Guinea).PLoS neglected tropical diseases · 2026Article
- Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof-of-Concept Study.ChemMedChem · 2026Article
- Draft genome sequence ofMicrobiology resource announcements · 2026Article
- Reversal of ATP synthase is a key attribute accompanying cellular differentiation of Trypanosoma brucei insect forms.Communications biology · 2026Article
- Vector competence re-evaluation of reared Glossina palpalis gambiensis for transmission of Trypanosoma congolense and Trypanosoma brucei brucei isolates for an experimental event.Parasites & vectors · 2026Article
- Efficacy of high doses of ivermectin-clorsulon in cattle on Glossina palpalis gambiensis survival and fecundity: implications for human and animal trypanosomoses control.Parasites & vectors · 2026Article
- Ruthenium-Catalyzed CH Alkenylation of Trypanocidal Naphthoquinones: A Mechanistic Benchmarking Study.ChemistryOpen · 2026Article
- African Trypanosomiasis Research at a Crossroads: Bibliometric and Systematic Insights for the Future.Journal of parasitology research · 2026Review
- Control of Human African Trypanosomiasis in the Nola-Bilolo Focus, Central African Republic, 2020-2024: Outcome of Capacity Building, Improved Diagnosis and Treatment.Journal of parasitology research · 2026Article
- Measuring elimination of gambiense human African trypanosomiasis: a comparison of deceptively different metrics.Parasites & vectors · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundIn the 20th century, epidemics of human African trypanosomiasis (HAT) ravaged communities in a number of African countries. The latest surge in disease transmission was recorded in the late 1990s, with more than 35,000 cases reported annually in 1997 and 1998. In 2013, after more than a decade of sustained control efforts and steady progress, the World Health Assembly resolved to target the elimination of HAT as a public health problem by 2020. We report here on recent progress towards this goal. METHODOLOGY/PRINCIPAL
findingsWith 992 and 663 cases reported in 2019 and 2020 respectively, the first global target was amply achieved (i.e. fewer than 2,000 HAT cases/year). Areas at moderate or higher risk of HAT, where more than 1 case/10,000 people/year are reported, shrunk to 120,000 km2 for the five-year period 2016-2020. This reduction of 83% from the 2000-2004 baseline (i.e. 709,000 km2) is slightly below the target (i.e. 90% reduction). As a result, the second global target for HAT elimination as a public health problem cannot be considered fully achieved yet. The number of health facilities able to diagnose and treat HAT expanded (+9.6% compared to a 2019 survey), thus reinforcing the capacity for passive detection and improving epidemiological knowledge of the disease. Active surveillance for gambiense HAT was sustained. In particular, 2.8 million people were actively screened in 2019 and 1.6 million in 2020, the decrease in 2020 being mainly caused by COVID-19-related restrictions. Togo and Côte d'Ivoire were the first countries to be validated for achieving elimination of HAT as a public health problem at the national level; applications from three additional countries are under review by the World Health Organization (WHO). CONCLUSIONS/SIGNIFICANCE: The steady progress towards the elimination of HAT is a testament to the power of multi-stakeholder commitment and coordination. At the end of 2020, the World Health Assembly endorsed a new road map for 2021-2030 that set new bold targets for neglected tropical diseases. While rhodesiense HAT remains among the diseases targeted for elimination as a public health problem, gambiense HAT is targeted for elimination of transmission. The goal for gambiense HAT is expected to be particularly arduous, as it might be hindered by cryptic reservoirs and a number of other challenges (e.g. further integration of HAT surveillance and control into national health systems, availability of skilled health care workers, development of more effective and adapted tools, and funding for and coordination of elimination efforts).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.